BioCardia (NASDAQ:BCDA) Stock Price Down 3.9% – Time to Sell?

Shares of BioCardia, Inc. (NASDAQ:BCDA) fell 3.9% on Wednesday . The company traded as low as $1.22 and last traded at $1.23. 42,279 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 75,777 shares. The stock had previously closed at $1.28.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $25.00.

BioCardia Trading Down 3.9%

The firm has a market capitalization of $13.05 million, a price-to-earnings ratio of -0.83 and a beta of 0.60. The stock’s 50-day moving average is $1.26 and its 200-day moving average is $1.38.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Cetera Investment Advisers acquired a new stake in shares of BioCardia during the 2nd quarter valued at $40,000. Geode Capital Management LLC increased its holdings in BioCardia by 70.4% in the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares in the last quarter. Finally, DRW Securities LLC bought a new position in BioCardia in the fourth quarter valued at about $72,000. 20.57% of the stock is currently owned by institutional investors.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.